Health Trials

Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

1

Review clinical trials related to Post Essential Thrombocythaemia Myelofibrosis (PET-MF). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled. Patients will continue to receive ruxolitinib at a stable dose and ropeginterferon alfa 2b will be added to the regimen.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The University of Hong KongUpdated: Jun 11, 2025Locations: 1
Eligibility criteria

Willing and able to provide informed consent [+8]

Prior or current use of interferon alfa (IFNα) preparations for MPN [+16]

Read more